Repair Biotechnologies is developing two distinct classes of therapy. The first program is focused on reversal of age-related thymic atrophy, a process that reduces the supply of naive T cells and consequently degrades immune function. The second program takes improvement of reverse cholesterol transport as the basis for approaches to reduce the size and prevalence of atherosclerotic lesions in older individuals, thus reducing risk of cardiovascular events.